DK133035B - Fremgangsmade til fjernelse af den analgetiske, euforiske eller fysiske afhengighedsvirkning fra et oralt virksomt analgetikum, nar det indgives parenteralt - Google Patents

Fremgangsmade til fjernelse af den analgetiske, euforiske eller fysiske afhengighedsvirkning fra et oralt virksomt analgetikum, nar det indgives parenteralt

Info

Publication number
DK133035B
DK133035B DK378571AA DK378571A DK133035B DK 133035 B DK133035 B DK 133035B DK 378571A A DK378571A A DK 378571AA DK 378571 A DK378571 A DK 378571A DK 133035 B DK133035 B DK 133035B
Authority
DK
Denmark
Prior art keywords
analgetic
euphorical
parentally
procedure
remove
Prior art date
Application number
DK378571AA
Other languages
Danish (da)
English (en)
Inventor
I J Pachter
M Gordon
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of DK133035B publication Critical patent/DK133035B/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK378571AA 1970-08-03 1971-08-03 Fremgangsmade til fjernelse af den analgetiske, euforiske eller fysiske afhengighedsvirkning fra et oralt virksomt analgetikum, nar det indgives parenteralt DK133035B (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6062170A 1970-08-03 1970-08-03

Publications (1)

Publication Number Publication Date
DK133035B true DK133035B (da) 1976-03-15

Family

ID=22030682

Family Applications (1)

Application Number Title Priority Date Filing Date
DK378571AA DK133035B (da) 1970-08-03 1971-08-03 Fremgangsmade til fjernelse af den analgetiske, euforiske eller fysiske afhengighedsvirkning fra et oralt virksomt analgetikum, nar det indgives parenteralt

Country Status (9)

Country Link
US (1) US3773955A (fr)
AU (1) AU463074B2 (fr)
BE (1) BE770625A (fr)
DE (1) DE2138593A1 (fr)
DK (1) DK133035B (fr)
FR (1) FR2101191B1 (fr)
GB (1) GB1353815A (fr)
NL (1) NL7109388A (fr)
ZA (1) ZA714683B (fr)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3885027A (en) * 1971-04-12 1975-05-20 West Laboratories Inc Orally administered drug composition for therapy in the treatment of narcotic drug addiction
US3896226A (en) * 1971-11-26 1975-07-22 Lewinstein Evalina 6-methylene-6-desoxy dihydro morphine and codeine derivatives and pharmaceutically acceptable salts thereof, and use of the same as a narcotic antagonist
US3906100A (en) * 1973-05-24 1975-09-16 Miles Lab N-benzyl-N-{8 2-phenyl-2-(4-phenyl-1-piperidyl)-ethyl{9 -propionamide para-chlorobenzene sulfonate
US4048316A (en) * 1974-03-04 1977-09-13 Penn Nathar W Composition for antagonizing the narcotic effects of barbiturate addiction and withdrawal effects, and for treatment of barbiturate poisoning
US4126684A (en) * 1976-02-11 1978-11-21 Ciba-Geigy Corporation 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
JPS56128715A (en) * 1980-03-06 1981-10-08 Bristol Myers Co Analgesic abuse prevention
US4366159A (en) * 1981-09-08 1982-12-28 Michael Richard Magruder Nalbuphine-narcotic analgesic composition and method of producing analgesia
DE3216327C1 (de) * 1982-05-03 1983-05-19 Siempelkamp Gießerei GmbH & Co, 4150 Krefeld Herstellung von dickwandigen Abschirmtransport- und Lagerbehältern aus sphärolitischem Gußeisen
AU8952282A (en) * 1982-08-25 1984-03-29 Joel E. Bernstein Method of treating pruritis and composition therefor
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4888346A (en) * 1986-10-07 1989-12-19 Bernard Bihari Method for the treatment of persons infected with HTLV-III (AIDS) virus
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
CA2095523C (fr) 1991-09-06 2004-06-22 Robert B. Raffa Composition comprenant du tramadol et de l'acetaminophene et son utilisation
US7027859B1 (en) 1994-09-26 2006-04-11 Alza Corporation Electrotransport delivery device having improved safety and reduced abuse potential
US5587381A (en) * 1995-03-27 1996-12-24 Sinclair; John D. Method for terminating methadone maintenance through extinction of the opiate-taking responses
EP1041988A4 (fr) 1997-12-22 2002-03-13 Euro Celtique Sa Procede prevenant l'abus des doses orales d'opioides
EP1041987B1 (fr) 1997-12-22 2006-04-19 Euro-Celtique S.A. Formulation pharmaceutique pour administration orale comprenant en combinaison un agoniste des récepteurs opiacés et la naltrexone
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
AU6934400A (en) 1999-08-25 2001-03-19 Barrett R. Cooper Compositions and methods for treating opiate intolerance
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
EP2092936B1 (fr) 2000-02-08 2013-03-20 Euro-Celtique S.A. Compositions orales inviolables comprenant des agonistes opioïdes
CA2446738C (fr) * 2001-05-11 2012-05-29 Endo Pharmaceuticals, Inc. Forme posologique d'opioides empechant la consommation abusive
EP1387673B1 (fr) 2001-05-11 2010-12-29 Endo Pharmaceuticals Inc. Forme posologique d'opioides a liberation prolongee empechant la consommation abusive
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US7968119B2 (en) * 2001-06-26 2011-06-28 Farrell John J Tamper-proof narcotic delivery system
SI1416842T1 (sl) 2001-07-18 2009-06-30 Euro Celtique Sa Farmacevtske kombinacije oksikodona in naloksona
IL160222A0 (en) 2001-08-06 2004-07-25 Euro Celtique Sa Opioid agonist formulations with releasable and sequestered antagonist
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US20030068276A1 (en) * 2001-09-17 2003-04-10 Lyn Hughes Dosage forms
US20040126428A1 (en) * 2001-11-02 2004-07-01 Lyn Hughes Pharmaceutical formulation including a resinate and an aversive agent
HUE032656T2 (en) * 2002-04-05 2017-10-30 Euro Celtique Sa Pharmaceutical composition containing oxicodone and naloxone
US20030199439A1 (en) * 2002-04-22 2003-10-23 Simon David Lew Compositions of alpha3beta4 receptor antagonists and opioid agonist analgesics
TW200404581A (en) * 2002-04-23 2004-04-01 Alza Corp Transdermal analgesic systems with reduced abuse potential
JP4694207B2 (ja) * 2002-07-05 2011-06-08 コルジウム ファーマシューティカル， インコーポレイテッド オピオイドおよび他の薬物に関する乱用抑止性の薬学的組成物
US8840928B2 (en) * 2002-07-05 2014-09-23 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US8557291B2 (en) 2002-07-05 2013-10-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US10004729B2 (en) 2002-07-05 2018-06-26 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
CN1703200B (zh) 2002-09-20 2012-02-29 奥尔制药公司 隔离亚单元和相关组合物及方法
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
MXPA05011071A (es) * 2003-04-21 2005-12-12 Euro Celtique Sa Forma de dosificacion resistente a la alteracion que comprende particulas co-extrusionadas de agente adverso y proceso de fabricacion de las misma.
US20040219195A1 (en) * 2003-04-30 2004-11-04 3M Innovative Properties Company Abuse-resistant transdermal dosage form
US7182955B2 (en) * 2003-04-30 2007-02-27 3M Innovative Properties Company Abuse-resistant transdermal dosage form
US8790689B2 (en) * 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
KR101159828B1 (ko) 2003-04-30 2012-07-04 퍼듀 퍼머 엘피 활성제 구성요소 및 활성제 층의 원위부에 억제제 구성요소를 포함하는 내변조성 경피제형
WO2004112756A1 (fr) 2003-06-26 2004-12-29 Isa Odidi Capsules contenant un inhibiteur de la pompe a protons comprenant des unites secondaires differemment structurees permettant une liberation retardee de l'ingredient actif
CA2543610A1 (fr) * 2003-10-30 2005-05-19 Alza Corporation Systemes analgesiques transdermiques reduisant les risques d'abus de consommation
ES2281851T3 (es) * 2003-12-09 2007-10-01 Euro-Celtique S.A. Forma de dosis co-extruida resistente a la manipulacion conteniendo un agente activo y un agente adverso y proceso para preparar el mismo.
US8883204B2 (en) * 2003-12-09 2014-11-11 Purdue Pharma L.P. Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
JP2007526796A (ja) * 2003-12-15 2007-09-20 アレックザ ファーマシューティカルズ， インコーポレイテッド 薬剤エアロゾル吸入による突出痛の治療
US20050165038A1 (en) * 2004-01-22 2005-07-28 Maxwell Gordon Analgetic dosage forms that are resistant to parenteral and inhalation dosing and have reduced side effects
KR100963914B1 (ko) 2004-03-30 2010-06-17 유로-셀띠끄 소시에떼 아노님 흡착제 및 억제제를 포함하는 내변조성 제형
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
EP1604666A1 (fr) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioides pour le traitement de la bronchopneumopathie chronique obstructive
EP1604667A1 (fr) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioides pour le traitement des impatiences des membres inférieurs
PT1765292T (pt) 2004-06-12 2017-12-29 Collegium Pharmaceutical Inc Formulações de fármacos dissuasoras de abuso
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
JP2008510713A (ja) * 2004-08-20 2008-04-10 スリーエム イノベイティブ プロパティズ カンパニー 半透明保護フィルムを有する経皮薬物送達デバイス
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
GEP20105052B (en) * 2005-01-28 2010-07-26 Euro Celtique Sa Alcohol resistant dosage forms
TW200640526A (en) * 2005-02-24 2006-12-01 Alza Corp Transdermal electrotransport drug delivery systems with reduced abuse potential
EP1695700A1 (fr) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Forme posologique contenant de l'oxycodone et de la naloxone
EP1702558A1 (fr) 2005-02-28 2006-09-20 Euro-Celtique S.A. Procédé et dispositif pour évaluer la fonction de l'activité intestinale
WO2006124585A2 (fr) * 2005-05-13 2006-11-23 Alza Corporation Systeme d'administration de galantamine a couches multiples equipe d'une protection contre l ecoulement un flux de matiere de reservoir
EP1893278A2 (fr) * 2005-06-03 2008-03-05 Trans-Dermal Patents Company, LLC Systeme d'administration d'agent
US20090143761A1 (en) * 2005-06-03 2009-06-04 Transdermal Patents Company, Llc Agent delivery system and uses of same
US8329744B2 (en) * 2005-11-02 2012-12-11 Relmada Therapeutics, Inc. Methods of preventing the serotonin syndrome and compositions for use thereof
WO2008134071A1 (fr) * 2007-04-26 2008-11-06 Theraquest Biosciences, Inc. Formulations multimodales à libération progressive résistantes aux emplois abusifs
US20090082466A1 (en) * 2006-01-27 2009-03-26 Najib Babul Abuse Resistant and Extended Release Formulations and Method of Use Thereof
WO2007056142A2 (fr) * 2005-11-02 2007-05-18 Theraquest Biosciences, Llc Procedes de prevention du syndrome serotoninergique et compositions utilisees a cette fin
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
EP1810670A1 (fr) * 2006-01-19 2007-07-25 Holger Lars Hermann Combinaison de Polamidone et de Naloxone dans le traitement de la toxicomanie
ZA200807571B (en) * 2006-03-01 2009-08-26 Ethypharm Sa Crush-resistant tablets intended to prevent accidental misuse and unlawful diversion
CA2648280C (fr) 2006-04-03 2014-03-11 Isa Odidi Dispositif d'administration a liberation commandee comprenant un enrobage organosol
US10960077B2 (en) * 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US20070278289A1 (en) * 2006-05-31 2007-12-06 Toshiba Tec Kabushiki Kaisha Payment adjusting apparatus and program therefor
SI2719378T1 (sl) 2006-06-19 2016-11-30 Alpharma Pharmaceuticals Llc Farmacevtski sestavki
EP1897543A1 (fr) 2006-08-30 2008-03-12 Euro-Celtique S.A. Gaufre de buprénorphine pour la thérapie de substitution
EP2121088B1 (fr) 2007-03-09 2016-07-13 Alexza Pharmaceuticals, Inc. Unité chauffante à utiliser dans un dispositif d'administration de médicament
US7748244B2 (en) * 2007-09-14 2010-07-06 Schlage Lock Company Deadbolt lock assembly
WO2009059048A2 (fr) * 2007-10-30 2009-05-07 The Regents Of The University Of Colorado Opioïdes-(+) et méthodes d'utilisation
US20100239523A1 (en) * 2007-10-30 2010-09-23 The Regents Of The University Of Colorado Tlr modulators and methods for using the same
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
SG174286A1 (en) 2009-03-10 2011-10-28 Euro Celtique Sa Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
AU2012219322A1 (en) 2011-02-17 2013-05-09 QRxPharma Ltd. Technology for preventing abuse of solid dosage forms
JP2016525138A (ja) 2013-07-23 2016-08-22 ユーロ−セルティーク エス．エイ． 疼痛および腸内ディスバイオシスをもたらす疾患および／または腸内細菌移行に対するリスクを高める疾患に罹患している患者における痛みの治療への使用のためのオキシコドンおよびナロキソンの組み合わせ
WO2016203061A1 (fr) 2015-09-03 2016-12-22 Acino Pharma Ag Réduction de la désallylation de la naloxone pendant le stockage d'une formulation à libération retardée contenant de la naloxone
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
US10532385B2 (en) 2016-06-29 2020-01-14 Disposerx, Inc. Disposal of medicaments
US12364668B2 (en) 2017-11-15 2025-07-22 The Regents Of The University Of California Treatment of opioid use disorder, opioid withdrawal symptoms, and chronic pain
EP3746138B1 (fr) 2018-02-02 2025-12-10 Alexza Pharmaceuticals, Inc. Dispositif aérosol à condensation électrique

Also Published As

Publication number Publication date
BE770625A (fr) 1972-01-28
FR2101191B1 (fr) 1975-02-07
GB1353815A (en) 1974-05-22
DE2138593A1 (de) 1972-03-30
US3773955A (en) 1973-11-20
NL7109388A (fr) 1972-02-07
ZA714683B (en) 1972-04-26
AU463074B2 (en) 1975-07-17
FR2101191A1 (fr) 1972-03-31
AU3185671A (en) 1973-02-01

Similar Documents

Publication Publication Date Title
DK133035B (da) Fremgangsmade til fjernelse af den analgetiske, euforiske eller fysiske afhengighedsvirkning fra et oralt virksomt analgetikum, nar det indgives parenteralt
DK143799C (da) Fremgangsmaade til fremstilling af n-1,1,1-trisubstituerede methylazoler
DK137451B (da) Analogifremgangsmåde til fremstilling af derivater af 2-oxo-pyrrolidin.
SE389526B (sv) Knut for forbindning av flera balkar, serskilt vid byggnadsskelett
DK138219B (da) Maskine til automatisk påsætning eller fjernelse af hætter på gasflasker.
DK127695B (da) Tårnstillads.
DK115916B (da) Fremgangsmåde til fremstilling af 1-(2'-desoxy-D-ribofuranosyl)-5-fluor-cytosiner eller 4-N-p-toluoylderivater deraf.
DK133682B (da) Analogifremgangsmåde til fremstilling af 3alfa-hydroxy-5alfa-pregn-1-en-20-oner eller 3alfa-hydroxy-17beta-alkoxykarbonyl-5alfa-androst-1-ener.
DK125791B (da) Analogifremgangsmåde til fremstilling af derivater af amfetamin eller amfetaminlignende forbindelser.
DK127431B (da) Analogifremgangsmåde til fremstilling af thiepinderivater eller syreadditionssalte deraf.
BG18828A3 (bg) Метод за получаване на 3-((3-ациламино-2,4-6- трийодфенокси)-алкокси)-2-алкил-пропинова киселина
DK133869C (da) Fremgangsmade til fremstilling af alkalimetalaluminiumalkoxider
DK125853B (da) Analogifremgangsmåde til fremstilling af 3-azetidinolderivater eller syreadditionssalte deraf.
DK132121C (da) Fremgangsmade til fremstilling af 17alfa-hydroxypregna-4,9(11)-dien-3,20-dion
DK129239B (da) Analogifremgangsmåde til fremstilling af dihydro-3-(4-hydroxy-4-piperidyl)-furanonderivater.
TR17430A (tr) Sarsinti azaltici,polioreueretan terkipleri
DK136037B (da) Analogifremgangsmåde til fremstilling af 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidin-4-carboxylsyrederivater eller syreadditionssalte deraf.
DK146015C (da) Analogifremgangsmaade til fremstilling af erythro- eller mesoformerne af 3,3'-difluor-4,4'-dihydroxydibenzylderivater
DK126045B (da) Fremgangsmåde til fremstilling af 1-(5-nitrothiazolyl-2)-2-oxo-tetrahydroimidazol.
DK129124B (da) Analogifremgangsmåde til fremstilling af 1-(3-cyano-3,3-diphenylpropyl)-4-phenylisonipecotinsyre eller syreadditionssalte deraf.
DK122126B (da) Analogifremgangsmåde til fremstilling af 3-azetidinol-derivater eller syreadditionssalte deraf.
BE751898A (nl) Steiger.
DK123293B (da) Analogifremgangsmåde til fremstilling af N-substitueret 1-(2-hydroxy-3-aminopropoxy)-9-fluorenon eller syreadditionssalte heraf.
DK138741B (da) Fremgangsmåde til fremstilling af 1-hydroxyalkyl-1,4-benzodiazepin-2-on-derivater eller syreadditionssalte deraf.
ES196125Y (es) Andamio colgante.